Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Related Citations for PubMed (Select 22315050)

1.

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10.

Modjtahedi H, Khelwatty SA, Kirk RS, Seddon AM, Essapen S, Del Vecchio CA, Wong AJ, Eccles S.

Br J Cancer. 2012 Feb 28;106(5):883-8. doi: 10.1038/bjc.2012.27. Epub 2012 Feb 7.

2.

Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy.

Modjtahedi H, Moscatello DK, Box G, Green M, Shotton C, Lamb DJ, Reynolds LJ, Wong AJ, Dean C, Thomas H, Eccles S.

Int J Cancer. 2003 Jun 10;105(2):273-80.

PMID:
12673691
3.

Specific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma.

McIntyre JB, Bose P, Klimowicz AC, Brockton NT, Petrillo S, Matthews W, Easaw J, Magliocco A, Dort JC.

PLoS One. 2012;7(2):e31723. doi: 10.1371/journal.pone.0031723. Epub 2012 Feb 16.

4.
5.

Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.

Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR.

Cancer Res. 1995 Oct 1;55(19):4375-82.

6.
7.

Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study.

Lee HJ, Xu X, Choe G, Chung DH, Seo JW, Lee JH, Lee CT, Jheon S, Sung SW, Chung JH.

Lung Cancer. 2010 Jun;68(3):375-82. doi: 10.1016/j.lungcan.2009.07.014. Epub 2009 Aug 26.

PMID:
19712993
8.

Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer.

Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C, Modjtahedi H.

Int J Oncol. 2005 Aug;27(2):317-25.

PMID:
16010411
9.

Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.

Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC, Gullick WJ, Old LJ, Burgess AW, Scott AM.

Int J Cancer. 2002 Mar 20;98(3):398-408.

PMID:
11920591
10.

Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.

Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, et al.

Cancer Res. 1995 Jul 15;55(14):3140-8.

11.

Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance.

Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD.

J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7.

PMID:
15290895
12.

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.

Clin Cancer Res. 2006 Sep 1;12(17):5064-73.

13.

The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.

Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM, Furnari FB.

Clin Cancer Res. 2007 Mar 15;13(6):1911-25.

14.

Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.

Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM.

Cancer Res. 2001 Jul 15;61(14):5355-61.

15.

Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).

Klausz K, Berger S, Lammerts van Bueren JJ, Derer S, Lohse S, Dechant M, van de Winkel JG, Peipp M, Parren PW, Valerius T.

Cancer Sci. 2011 Oct;102(10):1761-8. doi: 10.1111/j.1349-7006.2011.02019.x. Epub 2011 Aug 4.

PMID:
21718386
16.

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG.

Clin Cancer Res. 2005 Sep 1;11(17):6390-9.

17.
18.

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID.

Eur J Cancer. 2010 Jul;46(11):1997-2009. doi: 10.1016/j.ejca.2010.03.036. Epub 2010 Apr 21.

PMID:
20413299
19.

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.

Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, Ritter G, Cohen L, Scanlan MJ, Cavenee WK, Old LJ.

Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):639-44. Epub 2003 Jan 6. Erratum in: Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2163. Cavanee, Webster K [corrected to Cavenee, Webster K].

20.

Epidermal growth factor receptor expression in ameloblastoma.

Vered M, Shohat I, Buchner A.

Oral Oncol. 2003 Feb;39(2):138-43. Review.

PMID:
12509966
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk